Bristol-Myers Squibb second-quarter net sales increase 2 percent to $4.

Excellent results from a randomized Phase II study evaluating ipilimumab in conjunction with regular chemotherapy in previously untreated sufferers with advanced non-small cell lung cancer. These results were published in the New England Journal of Medication. SPRYCEL has been created in collaboration with Otsuka Pharmaceutical Co. In May, the Marketing Authorization Application for ipilimumab for metastatic melanoma in pre-treated individuals was validated by the European Medicines Agency. In April, the Type II Variation submission for SPRYCEL for the treating adult patients with recently diagnosed CML in chronic phase was validated by the European Medicines Agency. In July, U.S. Food and Medication Administration accepted for concern review the sNDA for SPRYCEL for the treating adult patients with recently diagnosed CML in persistent phase.Like all spider bites, the bite of the brown recluse may have two separate components. The most typical component may be the injury on the surface of the skin simply, referred to as the cutaneous lesion. Hardly ever, there can also be a systemic reaction to spider bites. In brown recluse bites, this systemic reaction can include a syndrome called systemic loxsoscelism, which includes a fever, muscle and rash pain. Systemic loxsoscelism can also be accompanied by hemolysis, where the membranes of the red blood cells rupture. Hemolysis can be life threatening, in children particularly. We have no idea why systemic loxsoscelism takes place in some people who have a dark brown recluse spider bite rather than in others, but it is life-threatening and does need immediate medical attention, said Tennessee Poison Center Medical Director Donna Seger, MD.